Laronidase

證據等級: L5

預測適應症: 10 個

Laronidase: From Mucopolysaccharidosis I (MPS I) to Lysosomal Storage Disease with Skeletal Involvement

One-Sentence Summary

Laronidase (Aldurazyme) is a recombinant human alpha-L-iduronidase used as enzyme replacement therapy (ERT) for Mucopolysaccharidosis type I (MPS I, including Hurler syndrome) — a rare lysosomal storage disorder caused by the hereditary deficiency of this enzyme. The TxGNN model predicts it may be effective for lysosomal storage disease with skeletal involvement, with 0 clinical trials and 4 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Mucopolysaccharidosis type I (MPS I / Hurler syndrome)
Predicted New Indication	Lysosomal storage disease with skeletal involvement
TxGNN Prediction Score	99.31%
Evidence Level	L3
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Laronidase is a recombinant human alpha-L-iduronidase — the enzyme that is deficient in MPS I. When this enzyme is absent, glycosaminoglycans (GAGs), specifically dermatan sulfate and heparan sulfate, progressively accumulate in tissues throughout the body. In the skeletal system, this GAG accumulation in bone matrix and connective tissue leads to the characteristic dysostosis multiplex, short stature, joint contractures, and ligamentous laxity that define the musculoskeletal phenotype of MPS I across its disease spectrum.

The mechanistic link to lysosomal storage disease with skeletal involvement is directly supported by experimental evidence. A key in vitro study (PMID 18758061) demonstrated that laronidase is taken up by both fibroblasts and osteoblasts via mannose-6-phosphate (M6P) receptors, is subsequently transported to lysosomes, and there cleaves accumulated substrates. This provides molecular-level proof that laronidase can act within bone-forming cells. Clinically, a 6.5-year observational follow-up of a patient with Scheie syndrome (attenuated MPS I, PMID 23127271) documents detailed skeletal monitoring — joint range of motion, skeletal radiographs — as primary outcome measures, confirming that skeletal manifestations are a core therapeutic target for ERT in MPS I.

This prediction is best understood as a formal classification of the skeletal manifestation subtype of MPS I, the drug’s already-approved indication, rather than a truly novel repurposing target. The biological overlap is very high. The primary uncertainty lies in disease classification boundaries rather than in mechanism, making this one of the highest-confidence, most clinically plausible predictions in this Evidence Pack.

Clinical Trials

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23127271	2012	Case report / observational	Pediatric Neurology	6.5-year ERT follow-up of a boy with Scheie syndrome (attenuated MPS I) initiated at age 2.5; detailed tracking of skeletal radiographs, joint range of motion, cardiac, ophthalmologic, and audiologic outcomes; disease progression observed despite therapy
18758061	2008	In vitro mechanistic study	Biological & Pharmaceutical Bulletin	Direct demonstration that laronidase is taken up by MPS I fibroblasts and osteoblasts via M6P receptors; enzyme transported to lysosomes and processes accumulated GAG substrates — key mechanistic evidence for skeletal cell activity
25345091	2014	Review	Pediatric Endocrinology Reviews	Comprehensive review of MPS I disease spectrum (Hurler, Hurler/Scheie, Scheie); describes skeletal involvement across phenotypes including dysostosis multiplex; covers diagnostic workup and treatment options
12196045	2002	Drug review	BioDrugs	Early development overview of laronidase; reports Phase I trial in MPS I patients; US and EU orphan drug designation; BioMarin-Genzyme joint venture background

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted indication — lysosomal storage disease with skeletal involvement — represents the skeletal phenotype of MPS I, the drug’s established therapeutic target. Direct in vitro evidence confirms that laronidase is active in osteoblasts, and clinical observational data document skeletal outcomes in ERT-treated MPS I patients. However, formal clinical endpoints specifically designed for skeletal disease, and complete safety documentation for Taiwan, are currently absent.

To proceed, the following is needed:

Retrieve TFDA SmPC or EMA SmPC (Aldurazyme) to complete safety evaluation — currently no warnings or contraindications data available in this pack (DG001, Blocking)
Document the full mechanism of action via DrugBank (DG002) — particularly CNS penetration limitations relevant to Hurler-type severe skeletal disease with concurrent neurological involvement
Identify or design clinical outcome measures specifically targeting skeletal endpoints (e.g., 6-minute walk test, joint range of motion, radiographic bone age) in MPS I ERT trials — existing Phase 3 data are broad somatic endpoints rather than skeletal-specific
Assess feasibility of Taiwan patient identification: MPS I is ultra-rare; newborn screening programs and registry data should be surveyed before any local study planning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.